Immunic Therapeutics
Manufacturing · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1200 Avenue of the Americas Ste 200, New...Phone Number
(332) 255-9811Website
www.imux.comRevenue
-Stock Symbol
IMUXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Immunic Therapeutics
Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases.Explore more
Immunic Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immunic Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Immunic Therapeutics recently announced quarterly report
Check out if Immunic Therapeutics is spiking on competitors!
Check if Immunic Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Immunic Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Immunic Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Immunic Therapeutics launches new products
Funding: Get notified immidiatlly once Immunic Therapeutics has new funding data
Click to see if Immunic Therapeutics had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Immunic Therapeutics
Compare insights from companies similar to Immunic Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Immunic Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Immunic Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Immunic Therapeutics.
Immunic Therapeutics financials insights
Gather financial insights about Immunic Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Share Placement
$60M
2026
Multiple Rounds
$1B
Immunic Therapeutics Tech Stack
A closer look at the technologies used by Immunic Therapeutics
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Lateral Move
Executive Move
Executive Moves, Lateral Move, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company
Event
Person-Based
Events, Podcast
Immunic Therapeutics News & Media
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
– Proven Leader with Deep Multiple Sclerosis Expertise; Played Key Role in the Launch of Ocrevus® – – Will Leverage Senior Global Executive and Commercial Experience to Support Immunic's Transition Toward a Commercial-Stage Multiple Sclerosis Company – NEW YORK, May 27, 2026 /PRNewswire/...EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO
Immunic, Inc (NASDAQ:IMUX) announced it strengthened its leadership team on Wednesday as the company prepares to advance its multiple sclerosis pipeline through late-stage development and potential commercialization. Immunic Appoints Erik Lundgren As CEO Immunic named biopharmaceutical executive Erik Lundgren as CEO effective May 22, 2026, with his employment beginning June 1. Lundgren succeeds Daniel Vitt, Ph.D., who will continue overseeing scientific strategy and portfolio advancement while rImmunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
– More Than 30 Years of Leadership Experience Across Biopharmaceutical Commercialization – – Played Key Role in the Launch and Commercial Success of Avonex® for Multiple Sclerosis – NEW YORK, May 19, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company...Immunic advances Phase 3 MS program, eyes topline data by year-end
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Wednesday it remains on track to deliver top-line Phase 3 data for its lead multiple sclerosis drug candidate, vidofludimus calcium, by the end of 2026, as the company strengthens its leadership team and bolsters its balance sheet with a recently...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Immunic Therapeutics
Sign Up For FreeTo access detailed company insights
Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases.... Read More
